RIGL insider filings
RIGEL PHARMACEUTICALS INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-03. Screen RIGL transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 4 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Schorno Dean L — EVP & Chief Financial Officer | 1 | — | — | 9 |
| Furey Raymond J. — EVP, GC, CCO & Corp Sec | 1 | — | — | 1 |
| RODRIGUEZ RAUL R — CEO, President, Director | 1 | — | — | 1 |
| Santos David A — EVP, Chief Commercial Officer | 1 | — | — | 1 |
Recent insider filings — RIGEL PHARMACEUTICALS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Furey Raymond J. — EVP, GC, CCO & Corp Sec | Tax withholding (F): 877 @ $47.50 | EDGAR |
| 2026-09-03 | 4 | RODRIGUEZ RAUL R — CEO, President, Director | Tax withholding (F): 2,424 @ $47.50 | EDGAR |
| 2026-09-03 | 4 | Santos David A — EVP, Chief Commercial Officer | Tax withholding (F): 874 @ $47.50 | EDGAR |
| 2026-09-03 | 4 | Schorno Dean L — EVP & Chief Financial Officer | Tax withholding (F): 928 @ $47.50 · Option exercise (M): 694 @ $12.70 · Option exercise (M): 620 @ $18.70 · Option exercise (M): 2,000 @ $24.20 · Option exercise (M): 1,286 @ $24.20 · Option exercise (M): 694 (derivative) @ $0 · +3 more | EDGAR |
| 2026-07-10 | 4 | HANNAH ALISON L. — EVP, Chief Medical Officer | Grant/award (A): 24,400 @ $0 | EDGAR |
| 2026-06-24 | 4 | Ali-Jackson Kamil — Director | Sale (S): 2,500 @ $35 | EDGAR |
| 2026-06-22 | 4 | Rojkjaer Lisa — EVP, Chief Medical Officer | Grant/award (A): 9,375 (derivative) @ $0 · Grant/award (A): 7,394 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Furey Raymond J. — EVP, GC, CCO & Corp Sec | Grant/award (A): 7,394 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | RODRIGUEZ RAUL R — CEO, President, Director | Grant/award (A): 31,700 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Santos David A — EVP, Chief Commercial Officer | Grant/award (A): 7,394 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Schorno Dean L — EVP & Chief Financial Officer | Grant/award (A): 7,394 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Schorno Dean L — EVP & Chief Financial Officer | Option exercise (M): 1,200 @ $18.70 · Option exercise (M): 2,181 @ $12.70 · Tax withholding (F): 928 @ $29.86 · Option exercise (M): 1,200 (derivative) @ $0 · Option exercise (M): 2,181 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Santos David A — EVP, Chief Commercial Officer | Tax withholding (F): 874 @ $29.86 | EDGAR |
| 2026-06-03 | 4 | Rojkjaer Lisa — EVP, Chief Medical Officer | Tax withholding (F): 850 @ $29.86 | EDGAR |
| 2026-06-03 | 4 | RODRIGUEZ RAUL R — CEO, President, Director | Tax withholding (F): 2,424 @ $29.86 | EDGAR |
| 2026-06-03 | 4 | Furey Raymond J. — EVP, GC, CCO & Corp Sec | Tax withholding (F): 877 @ $29.86 | EDGAR |
| 2026-05-28 | 4 | Ali-Jackson Kamil — Director | Sale (S): 2,500 @ $29.17 | EDGAR |
| 2026-05-19 | 4 | Wasman Jane — Director | Grant/award (A): 5,750 @ $0 | EDGAR |
| 2026-05-19 | 4 | MOOS WALTER H — Director | Grant/award (A): 5,750 @ $0 | EDGAR |
| 2026-05-19 | 4 | MILLER MICHAEL PATRICK — Director | Grant/award (A): 5,750 @ $0 | EDGAR |
| 2026-05-19 | 4 | LAPOINTE ANTHONY GREGG — Director | Grant/award (A): 5,750 @ $0 | EDGAR |
| 2026-05-19 | 4 | HANNAH ALISON L. — Director | Grant/award (A): 5,750 @ $0 | EDGAR |
| 2026-05-19 | 4 | Frohlich Mark W — Director | Grant/award (A): 5,750 @ $0 | EDGAR |
| 2026-05-19 | 4 | Ali-Jackson Kamil — Director | Grant/award (A): 5,750 @ $0 | EDGAR |
| 2026-02-24 | 4 | MOOS WALTER H — Director | Option exercise (M): 4,000 @ $24 · Sale (S): 4,000 @ $36.36 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Furey Raymond J. — EVP, GC, CCO & Corp Sec | Grant/award (A): 19,497 @ $0 | EDGAR |
| 2026-02-19 | 4 | RODRIGUEZ RAUL R — CEO, President, Director | Grant/award (A): 53,915 @ $0 | EDGAR |
| 2026-02-19 | 4 | Santos David A — EVP, Chief Commercial Officer | Grant/award (A): 19,430 @ $0 | EDGAR |
| 2026-02-19 | 4 | Rojkjaer Lisa — EVP, Chief Medical Officer | Grant/award (A): 18,894 @ $0 | EDGAR |
| 2026-02-19 | 4 | Schorno Dean L — EVP & Chief Financial Officer | Grant/award (A): 20,636 @ $0 | EDGAR |
| 2026-02-12 | 4 | Santos David A — EVP, Chief Commercial Officer | Tax withholding (F): 3,546 @ $34.62 | EDGAR |
| 2026-02-12 | 4 | Schorno Dean L — EVP & Chief Financial Officer | Tax withholding (F): 3,546 @ $34.62 | EDGAR |
| 2026-02-12 | 4 | Rojkjaer Lisa — EVP, Chief Medical Officer | Tax withholding (F): 3,758 @ $34.62 | EDGAR |
| 2026-02-12 | 4 | Furey Raymond J. — EVP, GC, CCO & Corp Sec | Tax withholding (F): 3,546 @ $34.62 | EDGAR |
| 2026-02-12 | 4 | RODRIGUEZ RAUL R — CEO, President, Director | Tax withholding (F): 7,607 @ $34.62 | EDGAR |
| 2026-02-04 | 4 | Santos David A — EVP, Chief Commercial Officer | Tax withholding (F): 5,718 @ $36.01 | EDGAR |
| 2026-02-04 | 4 | Schorno Dean L — EVP & Chief Financial Officer | Tax withholding (F): 5,488 @ $36.01 | EDGAR |
| 2026-02-04 | 4 | Furey Raymond J. — EVP, GC, CCO & Corp Sec | Tax withholding (F): 3,968 @ $36.01 | EDGAR |
| 2026-02-04 | 4 | RODRIGUEZ RAUL R — CEO, President, Director | Option exercise (M): 40,000 @ $27.40 · Tax withholding (F): 35,211 @ $37 · Option exercise (M): 40,000 @ $27.40 · Tax withholding (F): 35,424 @ $37 · Tax withholding (F): 14,110 @ $36.01 · Option exercise (M): 40,000 (derivative) @ $0 · +1 more | EDGAR |
| 2026-02-03 | 4 | MILLER MICHAEL PATRICK — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | Schorno Dean L — EVP & Chief Financial Officer | Option exercise (M): 1,987 @ $20 · Option exercise (M): 2,846 @ $24.20 · Option exercise (M): 1,667 @ $18.70 · Option exercise (M): 1,987 (derivative) @ $0 · Option exercise (M): 2,846 (derivative) @ $0 · Option exercise (M): 1,667 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | Schorno Dean L — EVP & Chief Financial Officer | Grant/award (A): 7,394 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | Santos David A — EVP, Chief Commercial Officer | Grant/award (A): 7,394 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | Rojkjaer Lisa — EVP, Chief Medical Officer | Grant/award (A): 7,394 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | Furey Raymond J. — EVP, GC, CCO & Corp Sec | Grant/award (A): 7,394 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | RODRIGUEZ RAUL R — CEO, President, Director | Grant/award (A): 31,700 (derivative) @ $0 | EDGAR |
| 2025-05-28 | 4 | MOOS WALTER H — Director | Grant/award (A): 2,500 @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-05-28 | 4 | LAPOINTE ANTHONY GREGG — Director | Grant/award (A): 2,500 @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-05-28 | 4 | HANNAH ALISON L. — Director | Grant/award (A): 2,500 @ $0 · Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-05-28 | 4 | Frohlich Mark W — Director | Grant/award (A): 1,250 @ $0 · Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
Recent 8-K events — RIGEL PHARMACEUTICALS INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-17 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets | EDGAR |
| 2026-05-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2026-03-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RIGL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs